GWSA
EDIT icon

Global Wealth Strategies & Associates’s Editas Medicine EDIT Stock Holding History

Global Wealth Strategies & Associates’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35
Closed -$86 – 196
2026
Q1 		$86 Hold
35
– – ﹤0.01% 520
2025
Q4 		$72 Sell
35
-125
-78% -$361 ﹤0.01% 532
2025
Q3 		$555 Buy
160
+35
+28% +$98 ﹤0.01% 445
2025
Q2 		$275 Hold
125
– – ﹤0.01% 351
2025
Q1 		$145 Buy
+125
New +$184 ﹤0.01% 457

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Global Wealth Strategies & Associates's EDIT Position: Q2 2026 in Review

Global Wealth Strategies & Associates sold out of Editas Medicine (EDIT) in Q2 2026, closing a stake of 35 shares — an estimated $86 sold.

Global Wealth Strategies & Associates first reported a position in EDIT in Q1 2025 and held it in 5 quarters. The position peaked at $555 in Q3 2025. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Global Wealth Strategies & Associates reported no remaining Editas Medicine position as of Q2 2026 after selling out during the quarter.
  • Global Wealth Strategies & Associates sold 35 Editas Medicine shares in Q2 2026, an estimated $86.
  • Global Wealth Strategies & Associates first reported a position in Editas Medicine in Q1 2025 and held it in 5 quarters.
  • Global Wealth Strategies & Associates's Editas Medicine position peaked at $555 in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Global Wealth Strategies & Associates's 13F filing for Q2 2026, filed 1 Jul 2026.